The latest interim data from XPAND, AirXpanders Inc.’s U.S.-based, head-to-head pivotal study of its new, needle-free, patient-controlled tissue expansion system for mastectomy patients undergoing breast reconstruction, continue to show superior

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field